AT-007
Sponsors
Applied Therapeutics Inc., Applied Therapeutics, Inc.
Conditions
Classic GalactosemiaHereditary Neuropathy Caused by SORD DeficiencySorbitol Dehydrogenase (SORD) Deficiency
Phase 1
Phase 2
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
CompletedNCT04902781
Start: 2021-03-20End: 2025-05-21Updated: 2025-10-29
Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency
CompletedNCT05397665
Start: 2022-01-01End: 2026-06-01Updated: 2026-06-09
A RandomIzed, Double-Blind, Placebo-CoNtrolled, Two-Part Study to Evaluate the Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients with SoRbitol Dehydrogenase (SORD) DEficiency
Active, not recruitingCTIS2024-518250-16-00
Start: 2022-10-20Target: 45Updated: 2025-12-18